These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 28480857)
1. COMBINED ANTIVIRAL TREATMENT OF HEPATITIS C VIRUS INFECTION WITH PEGYLATED INTERFERON (PEG-IFN) Α-2A (PEGFERON) AND RIBAVIRIN (COPEGUS) IN INMATES. Vashakidze E; Imnadze T Georgian Med News; 2017 Mar; (264):86-90. PubMed ID: 28480857 [TBL] [Abstract][Full Text] [Related]
2. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. Yu JW; Wang GQ; Sun LJ; Li XG; Li SC J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637 [TBL] [Abstract][Full Text] [Related]
3. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis C patients with genotype 1. Dogan UB; Atabay A; Akin MS; Yalaki S Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1082-5. PubMed ID: 23524524 [TBL] [Abstract][Full Text] [Related]
4. Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin in Pakistan. Gill U; Aziz H; Gill ML Int J Infect Dis; 2013 Nov; 17(11):e1017-21. PubMed ID: 23896656 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b. Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of standard antiviral therapy retreatment following interferon treatment failure in chronic hepatitis C patients]. Liu JP; Kang Y; Shang J; Ding GQ; Xiao EH; Wei JF; Cao Q Zhonghua Gan Zang Bing Za Zhi; 2013 Sep; 21(9):656-8. PubMed ID: 24160338 [TBL] [Abstract][Full Text] [Related]
7. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients]. He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456 [TBL] [Abstract][Full Text] [Related]
8. Early predictability of virological response in patients of chronic hepatitis-C with genotype-3, treated with pegylated interferon and ribavirin. Umar M; Khaar HU; Khan SA; Ahmed M; Ambreen S; Minhas ZM; Nazar M J Ayub Med Coll Abbottabad; 2014; 26(4):559-63. PubMed ID: 25672187 [TBL] [Abstract][Full Text] [Related]
9. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy. Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839 [TBL] [Abstract][Full Text] [Related]
10. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C. Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F; Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072 [TBL] [Abstract][Full Text] [Related]
11. Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a. Zhou YQ; Wang XH; Hong GH; Zhu Y; Zhang XQ; Hu YJ; Mao Q J Viral Hepat; 2011 Aug; 18(8):595-600. PubMed ID: 21105968 [TBL] [Abstract][Full Text] [Related]
12. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. Napoli N; Giannelli G; Antonaci A; Antonaci S J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592 [TBL] [Abstract][Full Text] [Related]
13. [The efficacy and prognostic predictors of different treatment courses with pegylated interferon α-2a and ribavirin combination in recurrent chronic hepatitis C patients]. Rao H; Yang R; Shang J; Xu X; Chen X; Dou X; Feng Y; Gao Z; Xie Q; Li J; You H; Chen G; Niu J; Gong G; Hou J; Chen H; Zhang D; Wei L Zhonghua Nei Ke Za Zhi; 2015 Aug; 54(8):699-704. PubMed ID: 26674626 [TBL] [Abstract][Full Text] [Related]
14. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals. Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297 [TBL] [Abstract][Full Text] [Related]
15. Hepatitis C Viral Kinetic Changes in a Retrospective Cohort Study of Chronic Hepatitis C Virus Egyptian Patients on Pegylated Interferon and Ribavirin Therapy. Esmat GE; Al Akel W; Abdel Aziz RA; Al Sayed Taha A; Sabry D; Rashed LA; Mostafa A; El Kazaz AY; Ahmed SH J Interferon Cytokine Res; 2016 Mar; 36(3):149-58. PubMed ID: 26982165 [TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin. Oze T; Hiramatsu N; Yakushijin T; Kurokawa M; Igura T; Mochizuki K; Imanaka K; Yamada A; Oshita M; Hagiwara H; Mita E; Ito T; Inui Y; Hijioka T; Tamura S; Yoshihara H; Hayashi E; Inoue A; Imai Y; Kato M; Yoshida Y; Tatsumi T; Ohkawa K; Kiso S; Kanto T; Kasahara A; Takehara T; Hayashi N J Viral Hepat; 2009 Aug; 16(8):578-85. PubMed ID: 19552663 [TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of pegylated interferon α-2b injection (Y shape, 40 kD) in treatment of patients with genotype 1/6 chronic hepatitis C]. Feng B; Shang J; Wu SH; Chen H; Han Y; Li YQ; Zhang DZ; Zhao LF; Wei SF; Mao Q; Yin CB; Han T; Wang MR; Chen SJ; Li J; Xie Q; Zhen Z; Gao ZL; Zhang YX; Gong GZ; Yang DL; Pan C; Sheng JF; Tang H; Ning Q; Shi GF; Niu JQ; Luo GH; Sun YT; You H; Wang GQ; Zhang LL; Peng J; Zhang Q; Liu JJ; Chen CW; Chen XY; Zhao W; Wang RH; Sun L; Wei L Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):187-194. PubMed ID: 28482405 [No Abstract] [Full Text] [Related]
18. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960 [TBL] [Abstract][Full Text] [Related]
19. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C. Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622 [TBL] [Abstract][Full Text] [Related]
20. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]